Accelerating Drug Development For Biologics: Flexible And Fast DNA-To-IND Programs
The development of novel biotherapeutics holds immense promise for treating a wide range of diseases. However, this process can be time-consuming and require customized solutions for each unique molecule.
This webinar dives into innovative strategies and best practices to streamline the pathway to clinical trials, boost productivity, and improve product yield. Explore Lonza's comprehensive drug substance/drug product DNA-to-IND programs, designed to expedite development for various modalities like monoclonal antibodies, bispecific antibodies, Fabs, Fc-fusions and non-Fc recombinant proteins.
A critical step towards IND approval is obtaining preclinical material for toxicology studies. We'll present a novel approach to fast-track this material supply, specifically highlighting a three-month timeline for monoclonal antibody drug substance and an additional two months for drug product.
Through expert presentations and real-world cases, attendees will gain valuable insights on how tailored approaches and innovative technologies can create fast and flexible development workflows, ultimately leading to rapid therapeutic breakthroughs.
Key Takeaways:
- Discover innovative strategies, technologies, and best practices to accelerate the clinical trial pathway for biologics, from standard antibodies to complex new formats.
- Learn about Lonza's comprehensive and integrated drug substance/drug product programs designed for expedited development across multiple modalities.
- Explore a novel approach to fast-track your drug substance and drug product supply for toxicology studies.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.